BRPI0414907A - formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas - Google Patents

formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas

Info

Publication number
BRPI0414907A
BRPI0414907A BRPI0414907-6A BRPI0414907A BRPI0414907A BR PI0414907 A BRPI0414907 A BR PI0414907A BR PI0414907 A BRPI0414907 A BR PI0414907A BR PI0414907 A BRPI0414907 A BR PI0414907A
Authority
BR
Brazil
Prior art keywords
oral
pharmaceutical agent
injectable
microparticles
topical
Prior art date
Application number
BRPI0414907-6A
Other languages
English (en)
Inventor
Howard Bernstein
Donald E Chickering Iii
Eric K Huang
Sridhar Narasimhan
Shaina Reese
Julie A Straub
Original Assignee
Acusphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acusphere Inc filed Critical Acusphere Inc
Publication of BRPI0414907A publication Critical patent/BRPI0414907A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçõES FARMACêUTICAS COM LIBERAçãO SUSTENTADA INJETáVEIS, ORAIS OU TóPICAS". Formulações farmacêuticas e métodos são proporcionados para a distribuição sustentada de um agente farmacêutico a um paciente através de injeção, através de administração oral ou através de administração tópica. A formulação injetável inclui micropartículas porosas as quais compreendem um agente farmacêutico e um material de matriz em que, quando de injeção da formulação, uma quantidade terapêutica ou profilaticamente eficaz do agente farmacêutico é liberada das micropartículas durante pelo menos 24 horas. A formulação oral inclui micropartículas porosas as quais compreendem um agente farmacêutico e um material de matriz em que uma quantidade terapêutica ou profilaticamente eficaz do agente farmacêutico é liberada das micropartículas durante pelo menos 2 horas após administração oral. A formulação tópica inclui micropartículas porosas as quais compreendem um agente farmacêutico e um material de matriz em que uma quantidade terapêutica ou profilaticamente eficaz do agente farmacêutico é liberada das micropartículas durante pelo menos 2 horas após administração tópica.
BRPI0414907-6A 2003-09-30 2004-09-27 formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas BRPI0414907A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50738403P 2003-09-30 2003-09-30
PCT/US2004/031570 WO2005032523A1 (en) 2003-09-30 2004-09-27 Injectable, oral, or topical sustained release pharmaceutical formulations

Publications (1)

Publication Number Publication Date
BRPI0414907A true BRPI0414907A (pt) 2006-11-07

Family

ID=34421616

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414907-6A BRPI0414907A (pt) 2003-09-30 2004-09-27 formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas

Country Status (8)

Country Link
US (2) US20050069591A1 (pt)
EP (1) EP1667659A1 (pt)
JP (1) JP2007533634A (pt)
CN (1) CN1856296A (pt)
BR (1) BRPI0414907A (pt)
CA (1) CA2533887A1 (pt)
IL (1) IL173571A0 (pt)
WO (1) WO2005032523A1 (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US6918561B2 (en) * 2002-10-31 2005-07-19 Yon So Chong Shell assembly for winding tire cord strip or belt cord strip
EP3597262B1 (en) 2002-12-20 2023-12-27 Xeris Pharmaceuticals, Inc. Formulation for intracutaneous injection
JP2007509949A (ja) * 2003-10-29 2007-04-19 アイデックス ラボラトリーズ，インコーポレイティド 薬理学的に活性な化合物の塩
TW200616589A (en) * 2004-10-08 2006-06-01 Noven Pharma Transdermal delivery of drugs based on crystal size
DE602006019074D1 (de) 2005-04-15 2011-02-03 Einstein Coll Med Vitamin k zur vorbeugung und behandlung von hautausschlag infolge einer anti-egfr-therapie
WO2007011743A2 (en) 2005-07-14 2007-01-25 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
EP1978933A2 (en) * 2005-12-15 2008-10-15 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US20070265329A1 (en) * 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
EP2043685B1 (en) 2006-07-03 2015-12-23 Genmab A/S Prevention of rash in patients undergoing anti-egfr therapy
US7772213B2 (en) * 2006-07-27 2010-08-10 Nathan Strick Composition for the treatment of inflammatory conditions
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
EP1946746A1 (en) * 2007-01-17 2008-07-23 Merz Pharma GmbH & Co. KGaA Particulate aqueous system for the preparation of a formulation for the treatment of adipose diseases
MX2009008294A (es) * 2007-02-02 2010-03-18 Univ Miami Dispositivos implantables hibridos terapeuticos.
US20080194478A1 (en) * 2007-02-09 2008-08-14 Gene Signal International Sa Wound healing agent and composition
WO2008106571A2 (en) * 2007-02-28 2008-09-04 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
US8057381B2 (en) * 2007-04-16 2011-11-15 Allen Iii William F Method and implant material for treatment of urinary incontinence
WO2008143906A2 (en) * 2007-05-14 2008-11-27 Sustained Nano Systems Llc Hypercompressed particles for controlled release of ophthalmic medications
US8071119B2 (en) * 2007-05-14 2011-12-06 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
US20090148498A1 (en) * 2007-05-14 2009-06-11 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
EP2164497B1 (en) * 2007-06-11 2018-08-15 Edge Therapeutics Inc. A drug delivery system for the prevention of cerebral vasospasm
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US8815953B2 (en) 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
WO2009143558A1 (en) * 2008-05-26 2009-12-03 Silphion Pty Limited Injectable formulations
WO2010119455A2 (en) * 2009-04-15 2010-10-21 Sun Pharma Advanced Research Company Ltd. An injectable sustained release pharmaceutical composition
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US10350364B2 (en) 2009-11-11 2019-07-16 Windgap Medical, Inc. Portable Drug Mixing and Delivery Device and Associated Methods
JP2013517294A (ja) * 2010-01-15 2013-05-16 リセラ，インク． 凍結乾燥ケーキ製剤
CN102834104A (zh) * 2010-02-22 2012-12-19 优势医疗公司 治疗脑的出血性病状的方法和组合物
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
UA111162C2 (uk) * 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
US9597531B2 (en) 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
EP2678001B1 (en) 2011-02-25 2017-04-05 South Dakota State University Polymer conjugated protein micelles
DK2683364T3 (en) 2011-03-10 2017-02-27 Xeris Pharmaceuticals Inc Stable formulations for parenteral injection of peptide drugs.
EA027744B1 (ru) 2011-10-31 2017-08-31 Ксерис Фармасьютикалс, Инк. Лекарственные формы для лечения сахарного диабета
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
WO2016028814A2 (en) 2014-08-18 2016-02-25 Windgap Medical, Inc Portable drug mixing and delivery device and associated methods
US10569017B2 (en) 2013-03-15 2020-02-25 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
JP6560187B2 (ja) 2013-03-15 2019-08-14 ウインドギャップ メディカル インコーポレイテッド 携帯型薬剤混合及び送達システム並びに方法
US9907910B2 (en) 2013-03-15 2018-03-06 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
SG11201507751YA (en) * 2013-03-21 2015-10-29 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
US9186817B2 (en) * 2013-08-01 2015-11-17 Sunny Pharmtech Inc. Method for preparing tobramycin sulfate powder
CA2957399C (en) 2014-08-06 2023-09-26 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US11116903B2 (en) 2014-08-18 2021-09-14 Windgap Medical, Inc Compression seal for use with a liquid component storage vial of an auto-injector
AU2016266657B2 (en) 2015-04-15 2020-09-17 Windgap Medical, Llc Removable actuating cap for use with an auto-injector assembly
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
EP3307245A1 (en) 2015-06-11 2018-04-18 Alrise Biosystems GmbH Process for the preparation of drug loaded microparticles
WO2017024032A2 (en) * 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
EP3313478B1 (en) 2015-08-13 2020-11-04 Windgap Medical, Inc. Mixing and injection device with sterility features
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
BR112018008415A2 (pt) 2015-10-27 2018-10-30 Eupraxia Pharmaceuticals Inc formulações de liberação sustentada de anestésicos locais
KR20170076965A (ko) * 2015-12-24 2017-07-05 롯데정밀화학 주식회사 히드록시프로필메틸 셀룰로오스 프탈레이트 입자 및 그 제조방법
CN109906114B (zh) 2016-10-07 2021-11-12 巴斯夫欧洲公司 球形微粒
EP3595776A4 (en) * 2017-03-17 2020-09-30 Flexion Therapeutics, Inc. FLUTICASONE SUSTAINED-RELEASE FORMULATIONS AND THEIR PROCEDURES FOR USE
EP3630061B1 (en) 2017-06-02 2024-04-03 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
US20210024715A1 (en) 2018-04-06 2021-01-28 Basf Se Spherical microparticles
WO2020240017A1 (en) * 2019-05-29 2020-12-03 Camurus Ab Lipid-controlled release compositions
CN114903857B (zh) * 2021-02-09 2023-06-06 鲁南制药集团股份有限公司 一种荆防颗粒及其制备方法
CN115702880B (zh) * 2021-08-12 2023-11-03 山东新时代药业有限公司 一种重组甘精胰岛素注射液及其制备工艺
CN115813863A (zh) * 2022-12-15 2023-03-21 广州因明生物医药科技股份有限公司 一种可自发团聚的微球及其制备方法
CN116650444B (zh) * 2023-07-31 2023-10-31 国药集团川抗制药有限公司 一种他克莫司缓释药物及其制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE93384T1 (de) * 1983-11-14 1993-09-15 Univ Kentucky Res Found Poroese mikrokugeln zur arzneistoffabgabe sowie verfahren zu deren herstellung.
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
PT85521B (pt) * 1986-08-11 1990-06-29 Innovata Biomed Ltd Processo para a preparacao de composicoes farmaceuticas que consistem em microcapsulas
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
ZA886284B (en) * 1987-08-31 1990-04-25 Advanced Polymer Systems Inc Controlled release formulations
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US6060069A (en) * 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US5327883A (en) * 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
AU680422B2 (en) * 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DK0679088T3 (da) * 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
SK51695A3 (en) * 1992-10-19 1995-11-08 Dura Pharma Inc Dry powder medicament inhaler
ES2231775T5 (es) * 1993-07-30 2011-02-02 Imcor Pharmaceutical Co. Composición de microburbujas estabilizadas para ecografía.
EP0998917A1 (en) * 1993-11-19 2000-05-10 Alkermes Controlled Therapeutics Inc. II Preparation of biodegradable microparticles containing a biologically active agent
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
US7052678B2 (en) * 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
KR100572171B1 (ko) * 1997-09-29 2006-04-19 넥타르 테라퓨틱스 투여량 계측 흡입기용 안정화 제제
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6337092B1 (en) * 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6451349B1 (en) * 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6306425B1 (en) * 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US7678364B2 (en) * 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
US6585957B1 (en) * 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
EP1129705A1 (en) * 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US6589557B2 (en) * 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
CA2433335C (en) * 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
GB0103348D0 (en) * 2001-02-10 2001-03-28 Medical Res Council Delivery of biologically active agents
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6551578B2 (en) * 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6962071B2 (en) * 2001-04-06 2005-11-08 Bracco Research S.A. Method for improved measurement of local physical parameters in a fluid-filled cavity
US6585967B2 (en) * 2001-07-05 2003-07-01 Closure Medical Corporation Adhesive treatment for tinea cruris
WO2003088946A1 (en) * 2002-04-19 2003-10-30 The Regents Of The University Of Michigan Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens
WO2003090717A1 (en) * 2002-04-23 2003-11-06 Nanotherapeutics, Inc Process of forming and modifying particles and compositions produced thereby
US6919068B2 (en) * 2002-05-17 2005-07-19 Point Biomedical Corporation Method of preparing gas-filled polymer matrix microparticles useful for echographic imaging
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging

Also Published As

Publication number Publication date
IL173571A0 (en) 2006-07-05
US20050069591A1 (en) 2005-03-31
CN1856296A (zh) 2006-11-01
WO2005032523A1 (en) 2005-04-14
JP2007533634A (ja) 2007-11-22
CA2533887A1 (en) 2005-04-14
EP1667659A1 (en) 2006-06-14
US20070264343A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
BR0109875A (pt) Tratamento de doenças respiratórias
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
ECSP056076A (es) Sistema de suministro para droga y terapia celular
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
AR041913A1 (es) Formulaciones de deposito de liberacion controlada
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
AR069572A1 (es) Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
MXPA06000243A (es) Formulacion farmaceutica liofilizada estable de tetrodotoxina.
BRPI0510855A (pt) medicamento em forma de pelìcula para ministração oral e uso de estriol e/ou de ésteres de estriol farmaceuticamente aceitáveis
PT1305057E (pt) Composicao de biomateria microparticular para uso medicinal

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.